Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor
(CAR) is rapidly emerging as a promising new treatment for haematological and non …

Immune effector cells, including T cells and natural killer cells, which are genetically
engineered to express a chimeric antigen receptor (CAR), constitute a powerful new class of …

In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children
and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia …

Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone
marrow; secrete hematopoietic cytokines; support hematopoietic progenitors in vitro; and …

Background Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …

Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …

Virus-specific T cell (VST) lines could provide useful antiviral prophylaxis and treatment of
immune-deficient patients if it were possible to avoid the necessity of generating a separate …

Autologous T cells expressing a CD19-specific chimeric antigen receptor (CD19. CAR) are
active against B-cell malignancies, but it is unknown whether allogeneic CD19. CAR T cells …

Background Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-
blood transplantation. We hypothesized that engraftment would be improved by …

BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs)
improve outcomes for CD19-expressing B cell malignancies. We evaluated a human …